GermanyGermany

Drop in biotech investments in Europe

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst, painted a bleak picture. Investments in European biotechnology seem to be drying up. In the third quarter of 2011, companies attracted €163m for 29 deals, a report stated. That is 44% less than in the second quarter. Investments over all industries fell to an 11-year low in Europe, with a 12% drop, but biotech has been hit especially hard. Just last week Sanofi CEO Chris Viehbacher told Associated Press: "It has never been more difficult to fund a new idea. Venture capital has pretty much gotten right out of healthcare". He seemed self critical. "There has to be a greater demonstration that we can convert a great idea scientifically into a patient benefit with increased frequency — and faster. "A ray of hope comes out of the USA. Venture capitalists plan to invest increasingly in European biotech firms instead of US-firms, a survey by the National Venture Capital Association (NVCA) stated. The NVCA asked 150 venture capital firms – which put over US$10 billion into health-care companies over the past 3 years – about their investment plans for the next 3 years. 36% of respondents plan to increase investment in life science companies in Europe, whereas only 13% plan to increase investment in the United States. Correspondingly, 31% of firms said they plan to decrease investment in life science companies in the United States, compared with 7% that plan to decrease investment in Europe. But Asia beats them all: 44% of respondents also said they plan to increase investment in Asia, and none said they plan to decrease investment in the region.

GermanyGermany

05.08.2011

Boehringer Ingelheim is the first around the post. The European Commission cleared the German company's oral anticoagulant Pradaxa (dabigatran etexilate) for preventing stroke in atrial fibrillation patients at risk of stroke....

GermanyGermany

27.07.2011

Berlin – Reprogramming fibroblasts into human induced pluripotent stem cells (hiPSCs) can cause mitochondrial diseases, according to two reseearch groups from Berlin-based Max Planck Institute for Molecular Genetics. In every...

Germany, UKGermany

21.07.2011

In a first for European drug research, scientists have launched a clinical trial of an anti-HIV biotech medicine produced using genetically modified tobacco. Transgenic tobacco plants are grown for 45 days before being processed...

Germany, SwitzerlandGermany

19.07.2011

Basel - Roche goes shopping in Germany. The Swiss pharmaceutical giant agreed to buy privately-held mtm laboratories, a specialist in diagnostics for detecting cervical cancer based in Heidelberg, for up to 190 million...

GermanyGermany

08.07.2011

German pharmaceutical major Merck Serono has appointed Annalisa Jenkins as global head of drug development. The former head of Bristol-Myers Squibb’s global medical group is to lead her employer's drug development operations from...

GermanyGermany

08.07.2011

German pharmaceutical major Merck Serono has appointed Annalisa Jenkins as global head of drug development. The former head of Bristol-Myers Squibb’s global medical group is to lead her employer's drug development operations from...

Displaying results 31 to 40 out of 454

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/3/article/drop-in-biotech-investments-in-europe.html

Image Gallery

Stock list

All quotes

TOP

  • CYTOS (CH)0.23 CHF53.3%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CO.DON (D)3.40 EUR9.7%

FLOP

  • WILEX (D)0.88 EUR-15.4%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)11.01 USD-13.5%

TOP

  • CO.DON (D)3.40 EUR91.0%
  • WILEX (D)0.88 EUR51.7%
  • BIOTECH PHARMACON (N)17.50 NOK50.9%

FLOP

  • CYTOS (CH)0.23 CHF-92.0%
  • BIONOR PHARMA (N)2.11 NOK-47.9%
  • GW PHARMACEUTICALS (UK)219.50 GBP-46.5%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP5900.0%
  • IXICO (UK)69.50 GBP776.4%
  • PLETHORA (UK)11.00 GBP609.7%

FLOP

  • CYTOS (CH)0.23 CHF-94.7%
  • EVOCUTIS (UK)0.22 GBP-92.9%
  • AGENNIX (D)0.04 EUR-78.9%

No liability assumed, Date: 15.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper